500
Participants
Start Date
February 7, 2024
Primary Completion Date
December 31, 2029
Study Completion Date
December 31, 2038
Delandistrogene Moxeparvovec
No study medication will be provided by the sponsor during this study.
Standard of Care
No study medication will be provided by the sponsor during this study.
Penn State Health Milton S. Hershey Medical Center, Hershey
Children's Hospital of Philadelphia, Philadelphia
Children's National Medical Center, Washington D.C.
University of Virginia, Charlottesville
Children's Hospital of the King's Daughters, Norfolk
Nemours Children's Hospital - Orlando, Orlando
Nicklaus Children's Hospital, Miami
All Children's Research Institute, Inc, St. Petersburg
Vanderbilt University Medical Center, Nashville
Le Bonheur Children's Hospital, Memphis
Indiana Clinical and Translational Science Institute, Indianapolis
University of Michigan, Ann Arbor
University of Kansas Medical Center, Kansas City
Arkansas Children's Hospital, Little Rock
Cook Children's Hospital, Fort Worth
University of Colorado - PPDS, Aurora
Children's Hospital Los Angeles - PIN, Los Angeles
OHSU Healthcare (Oregon Health and Science University), Portland
Seattle Children's Hospital, Seattle
Ann and Robert H Lurie Childrens Hospital of Chicago, Chicago
The Board of Regents of the University of Wisconsin, Madison
The Medical College of Wisconsin, Milwaukee
Sarepta Therapeutics, Inc.
INDUSTRY